2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

On November 15, 2021 Novocure (NASDAQ: NVCR) reported that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the phase 2 pilot 2-THE-TOP trial testing the safety and efficacy of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM) (Press release, NovoCure, NOV 15, 2021, View Source [SID1234595639]). In patients with greater than 9 months of follow-up, median progression-free survival, the primary endpoint, was at least 11.2 months. 24% of patients achieved partial to complete response. Dr. Tran will present these data at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting in Boston on November 19, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data show that Tumor Treating Fields have the potential to activate the pathways needed to create an effective, anti-cancer environment in the tumor," said Dr. Ely Benaim, Novocure’s Chief Medical Officer. "The results published today suggest a potential paradigm shift in how we approach treatment of patients with newly diagnosed glioblastoma."

"We are very encouraged by the results of the 2-THE-TOP study, especially in light of the poor prognostic factors of the patient population," said William Doyle, Novocure’s Executive Chairman. "Dr. Tran’s research is an important continuation of our exploration of synergies between TTFields and immunotherapy agents. We would like to thank Dr. Tran and the patients enrolled in the 2-THE-TOP trial for their ingenuity and courage."

Twenty-five patients with a median age of 61 years were enrolled in the 2-THE-TOP study, with a median follow-up of 14.7 months. Eight (32%) had biopsy only and partial resection, respectively. Eighteen (72%) had unmethylated MGMT and 3 (12%) had an IDH mutation. Twelve (48%) were progression-free, and 15 (60%) were still alive. Of the 19 patients with follow-up greater than 9 months, the median progression-free survival was at least 11.2 months compared to 6.7 months from the historical control study, EF-14, in which patients received TTFields and adjuvant temozolomide. Six (24%) patients with measurable tumors achieved partial or complete response. 193,760 peripheral blood mononuclear cells were sequenced in 12 patients before pembrolizumab and detected robust post-TTFields T cell activation in 11 of 12 patients via the T1IFN trajectory with a strong correlation with the TCRαβ clonal expansion Simpson index (Spearman coefficient r=-0.8, P=0.014). The study defined a T cell-based gene signature of TTFields effects on TCRαβ clonal expansion. The most common adverse events were thrombosis (4 patients, 16%), seizure (3 patients, 12%), and metabolic disturbances (2 patients, 8%).

The 2-THE-TOP trial is a phase 2 pilot trial designed for the treatment of patients with newly diagnosed GBM. Patients enrolled in the trial underwent maximal tumor resection followed by standard chemoradiation. Following the completion of chemoradiation, patients began a course of monthly cycles of adjuvant temozolomide. Treatment with TTFields started at approximately the same time as the first cycle of adjuvant temozolomide. Pembrolizumab was introduced in the second cycle of treatment and subsequent cycles of pembrolizumab were administered every three weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.

About EF-14

The EF-14 trial was a randomized, phase 3 pivotal trial which compared, post radiation, TTFields plus temozolomide versus temozolomide alone for the treatment of newly diagnosed GBM. Median progression-free survival, the primary endpoint, was 6.7 months for TTFields plus temozolomide versus 4.0 months for temozolomide alone. Median overall survival was 20.9 months for TTFields plus temozolomide versus 16.0 months for temozolomide alone.

About Tumor Treating Fields

Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. Fundamental scientific research extends across more than two decades and, in all preclinical research to date, TTFields have demonstrated a consistent anti-mitotic effect. TTFields therapy is intended principally for use together with other standard-of-care cancer treatments. There is a growing body of evidence that supports TTFields’ broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields therapy has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common side effect. The TTFields global development program includes a network of preclinical collaborators and a broad range of clinical trials across all phases, including four phase 3 pivotal trials in a variety of tumor types. To date, more than 20,000 patients have been treated with TTFields therapy.

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting

On November 15, 2021 Novocure (NASDAQ: NVCR) reported 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in Boston (Press release, NovoCure, NOV 15, 2021, View Source [SID1234595638]). The presentations cover a broad range of topics, with 22 of the 31 presentations prepared by external authors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One of the oral presentations will feature updated data from the 2-THE-TOP study treating 25 patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide. In patients with greater than 9 months of follow-up, median progression-free survival, the primary endpoint, was at least 11.2 months with activation of adaptive immunity.

"We are excited to gather, participate and share information on Tumor Treating Fields at the SNO 2021 Annual Meeting, one of the most important neuro-oncology conferences worldwide," said Dr. Ely Benaim, Novocure’s Chief Medical Officer. "More than 300 presentations on Tumor Treating Fields have been shared at SNO over the past 14 years. We look forward to driving further awareness and understanding of our therapy as an important treatment for solid tumors."

Oral Presentations

(CTIM-16) Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed GBM (2-THE-TOP trial). Lead author and presenter: David D. Tran. 5:05 p.m. to 5:10 p.m. EST Friday, Nov.19. (Clinical Trials Session I)

Induction of anti-tumor immunity in glioblastoma using Tumor Treating Fields. Presenter: David D. Tran. 11:30 a.m. to 11:50 a.m. EST Sunday, Nov. 21. (Emerging Technologies in Radiation Science Session)

Poster Presentations

All occurring 7:30 p.m. to 9:30 p.m. EST Friday, Nov. 19 in Exhibit Hall D

Clinical

(INNV-22) Factors guiding the initiation of Tumor Treating Fields (TTFields; 200 kHz) therapy for glioblastoma: self-reported patient and oncologist perspectives. Lead author and presenter: Peggy Frongillo.

(SURG-06) The safety profile of Tumor Treating Fields (TTFields; 200 kHz) concomitant with ventriculo-peritoneal shunts in patients with glioblastoma and hydrocephalus. Lead author: Nancy Ann Oberheim-Bush. Presenter: Wenyin Shi.

(CTNI-09) TRIDENT phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly-diagnosed glioblastoma. Lead author and presenter: Wenyin Shi.

(QOLP-31) Quality of life of patients with newly diagnosed glioblastoma during TTFields therapy in routine clinical care: first results of the TIGER study. Lead author and presenter: Oliver Bähr.

(INNV-07) TTFields treatment of gliosarcoma and recurrent anaplastic oligodendroglioma. Lead author and presenter: Nicholas A. Blondin.

(INNV-10) TTFields as maintenance therapy for an oligodendroglioma case and long-term follow-up. Lead author and presenter: Uvin Ko.

(CTNI-11) Tumor Treating Fields combined with second-line chemotherapy in recurrent glioblastoma: a matched retrospective study. Lead author and presenter: Yonggao Mou.

(CTNI-52) Retrospective analysis of using radiotherapy with concurrent temozolomide and Tumor Treating Fields for Chinese patients with newly diagnosed glioblastoma. Lead author and presenter: Yang Wang.

(NCOG-14) Real-World retrospective analysis of Tumor Treating Fields in the treatment of high-grade glioma based on Chinese population. Lead author and presenter: Zhiyong Qin.

(NIMG-34) Delayed pseudoprogression in glioblastoma patients treated with TTFields: a report of two cases. Lead author and presenter: Norihiko Saito.

(CTNI-38) PriCoTTF trial: a phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. Lead author and presenter: Sied Kebir.

(RADT-13) SPARE trial: Scalp-sparing radiation with concurrent temozolomide and Tumor Treating Fields for patients with newly diagnosed glioblastoma. Lead author and presenter: Ryan C. Miller.

(CTNI-19) Concurrent chemoradiation and Tumor Treating Fields (TTFields; 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence. Lead author and presenter: Ayesha S. Ali.

(RADT-22) Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: analysis of a pilot clinical trial. Lead author and presenter: Muneeb Niazi.

(INNV-18) Effect of duration of Tumor Treating Fields therapy on cellularity distributions beyond T1w MRI contrast enhancing margin at autopsy in glioma patients: preliminary results. Lead author and presenter: Samuel Bobholz.

(INNV-13) Understanding factors that influence the decision of accepting Tumor Treating Fields therapy. Lead author and presenter: Priya U. Kumthekar.

(QOLP-10) A longitudinal observational study of exercise behavior in glioblastoma patients treated with Tumor Treating Fields. Lead author and presenter: Katherine B. Peters.

Preclinical

(EXTH-75) Application of Tumor Treating Fields (TTFields) to the head and torso of mice with the dedicated inovivo system. Lead author: Shiri Davidi. Presenter: Moshe Giladi.

(EXTH-74) Increasing cancer cell membrane permeability through application of Tumor Treating Fields (TTFields). Lead author: Tali Voloshin. Presenter: Moshe Giladi.

(DDRE-46) Reduced cancer cell sensitivity to Tumor Treating Fields (TTFields) through activation of the PI3K/AKT/mTOR signaling pathway can be mitigated using PI3K inhibitors or PI3K/mTOR dual inhibitors. Lead author: Anat Klein-Goldberg. Presenter: Moshe Giladi.

(EXTH-05) Tumor Treating Fields in combination with the TERT-inhibitor eribulin have synergistic antiproliferative effects on human glioblastoma cells. Lead author: Piet Beusker. Presenter: Marco Stein.

(CBIO-02) In vitro Tumor Treating Fields (TTFields) reduce proliferation and alter MLH1 expression in temozolomide resistant (TMZR) patient-derived glioblastoma (GBM) cells. Lead author and presenter: Sharon K. Michelhaugh.

(CSIG-09) Assessment of Tumor Treating Fields (TTFields) combined with trichostatin A (TSA) in patient-derived glioblastoma (GBM) cells. Lead author and presenter: Manxiu Ma.

(DDRE-13) Prostaglandin E receptor 3 (PTGER3) regulates resistance to Tumor Treating Fields (TTFields) in glioblastoma cells. Lead author and presenter: Dongjiang Chen.

(IMMU-35) Induction of anti-tumor immunity by Tumor Treating Fields (TTFields) in glioblastoma. Lead author and presenter: Dongjiang Chen.

(EXTH-76) Developing the novel combination therapy options for cancer therapy using Tumor Treating Fields together with the chemo agents targeting the replication stress pathway. Lead author and presenter: Narasimha Kumar Karanam.

Physics

(RBIO-01) Developing the framework for Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord. Lead author: Jennifer de Los Santos. Presenter: Tal Marciano.

(RBIO-06) Mechanism of action and associated effects of Tumor Treating (TTFields) on living cells using simulations. Lead author and presenter: Tal Marciano.

(CTNI-44) Dosimetric impact of Tumor Treating Fields on concurrent radiation therapy for pediatric brain tumors. Lead author and presenter: Michelle Quan.

About Tumor Treating Fields

Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. Fundamental scientific research on TTFields extends across more than two decades and, in all preclinical research to date, TTFields have demonstrated a consistent anti-mitotic effect. TTFields therapy is intended principally for use together with other standard-of-care cancer treatments. There is a growing body of evidence that supports TTFields’ broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields therapy has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common side effect. The TTFields global development program includes a network of preclinical collaborators and a broad range of clinical trials across all phases, including four phase 3 pivotal trials in a variety of tumor types. To date, more than 20,000 patients have been treated with TTFields therapy.

BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA

On November 15, 2021 AOP Orphan reported in-licensed the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in Polycythaemia Vera (PV), a rare disease, and other myeloproliferative neoplasms (MPNs) for European, Commonwealth of Independent States (CIS), and Middle Eastern markets. Based on a pivotal study development program, which included the studies PEGINVERA, PROUD-PV and CONTINUATION-PV the European Medicines Agency (EMA) authorized BESREMi for the treatment of PV in February 2019 (Press release, AOP Orphan Pharmaceuticals, NOV 15, 2021, View Source [SID1234595637]). The whole clinical development program was designed and conducted by AOP Orphan in Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaEssentia Corp., AOP Orphan’s licensor, subsequently submitted the clinical data generated in the clinical development program for marketing authorisation of BESREMi by the FDA in the United States. On March 12, 2021, according to PharmaEssentia, the FDA issued a Complete Response Letter for BESREMi (Ropeginterferon alfa-2b) confirming the safety and efficacy of BESREMi in compliance with FDA regulations. Now, after PharmaEssentia’s manufacturing sites in Taiwan have successfully passed the FDA’s GMP pre-approval inspection in September 2021, the FDA approved BESREMi for sale in the United States.

"FDA’s confirmation of BESREMi’s safety and efficacy, based on AOP Orphan’s clinical study program and scientific knowledge, attests to the quality of work at our company" says Dr. Rudolf Widmann, Member of the Governing Board of AOP Orphan International. "We are extremely happy that now patients in the US have access for treating this rare blood cancer disease. This is the first of AOP Orphan’s ambitious projects to get medicinal products for rare and special diseases approved in the US. This achievement speaks not only to the scientific expertise and clinical development know-how of AOP Orphan, but also supports our company strategy to make drugs for rare and special diseases available worldwide."

Clinical studies conducted by AOP Orphan

Ropeginterferon alfa-2b is a specifically modified pegylated Interferon alpha 2b invented by PharmaEssentia’s CEO KC Lin.

The application of this third-generation interferon to the treatment of PV was invented by Dr. Rudolf Widmann of AOP Orphan: The company has continually invested in its hematology and drug development know-how to get an injection pen for patients’ at-home self-administration approved. Several clinical studies have been conducted by the company leading to a successful marketing authorization of BESREMi for the treatment of Polycythaemia Vera in the EU in February 2019, in Switzerland and in Taiwan in 2020, in Israel and Korea in 2021.

Besides achieving high rates of complete hematologic responses including freedom of phlebotomy in 8 out of 10 patients, BESREMi offers the possibility of disease modification and eventually operational cure in a subset of patients. This is exemplified by a decrease of mutant JAK2 allele burden (the disease-causing oncogene) from 37.3% at baseline to 7.3% in patients receiving Ropeginterferon alfa-2b, while an increase from 38.1% to 42.6% in the control group receiving hydroxyurea/best available therapy was observed (p<0.0001).1

Polycythaemia Vera patients in approximately 20 European countries are already being treated with Ropeginterferon alfa-2b. AOP Orphan is continuously working on increasing access for many more patients and continues the clinical development of BESREMi.

About BESREMi
BESREMi is a long-acting, mono-pegylated proline interferon (ATC L03AB15). Its unique pharmacokinetic properties offer a new level of tolerability. BESREMi is designed to be conveniently self-administered subcutaneously with a pen once every two weeks, or monthly after stabilization of hematological parameters. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. Ropeginterferon alfa-2b was discovered by PharmaEssentia, a long-term partner of AOP Orphan.

For the EMA Summary of Product Characteristics please visit: View Source

Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

On November 15, 2021 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, reported financial results for the quarter ended September 30, 2021 (Press release, Gamida Cell, NOV 15, 2021, View Source [SID1234595636]). Net loss for the third quarter of 2021 was $19.6 million, compared to a net loss of $14.8 million for the same period in 2020. As of September 30, 2021, Gamida Cell had total cash and cash equivalents of $120.8 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the past quarter, Gamida Cell:

Continued to execute on plans to submit a Biologic License Application (BLA) for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. As previously disclosed, in a recent pre-BLA meeting, the FDA requested a revised analysis of the manufacturing data generated at Gamida Cell’s wholly owned commercial manufacturing facility to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study. The FDA did not request additional clinical data to initiate the BLA submission once analytical comparability is demonstrated.
Progressed activities with objective to address the FDA’s Clinical Hold on the Investigational New Drug (IND) application for GDA-201, which was imposed based on questions about donor eligibility procedures and sterility assay qualification prior to the initiation of the study in patients with follicular and diffuse large B-cell lymphomas.
Expanded the company’s NAM-enabled natural killer (NK) cell pipeline targeting solid-tumor and hematological cancers, including genetically modified variants of proprietary NK therapies using both CRISPR/Cas9 and CAR methodologies.
"We are committed to advance our programs and bring our important potential therapies to patients as quickly as possible. We are working diligently to respond to the FDA’s information requests for omidubicel and GDA-201, and now expect to submit the BLA for omidubicel to the FDA in the first half of 2022 and we hope to promptly address outstanding issues regarding our IND application relating to GDA-201." said Julian Adams, Ph.D., chief executive officer of Gamida Cell. "Additionally, at our recent NK-focused R&D Day, we provided details on our genetically modified NK cell immunotherapy programs leveraging CAR- and CRISPR-mediated strategies against hematologic malignancies and solid tumors. The company remains focused on our goal of bringing patients with cancer potentially curative cell therapies."

Recent Developments and Planned Presentations at ASH (Free ASH Whitepaper)

Omidubicel: Advanced Cell Therapy

BLA Submission: During a recent pre-BLA meeting, the FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell’s wholly owned commercial manufacturing facility. Upon completing those requirements, the company anticipates submitting the BLA in the first half of 2022.
New data to be presented at ASH (Free ASH Whitepaper): Gamida Cell will have three omidubicel presentations – two presentations of additional data from the phase III randomized trial of omidubicel, and a poster presentation summarizing long term omidubicel data from multiple studies – at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (December 11-14, 2021).
Oral presentation of "Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel is Associated with Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood Transplantation" on Saturday, December 11, 2021, at 4:30 p.m. ET. Data collected from a subset of 37 patients in the omidubicel Phase III trial shows that, in addition to more rapid short-term hematopoietic recovery, omidubicel-treated patients had more rapid recovery of a wide variety of immune cells including CD4+ T cells, B cells, monocytes, natural killer cells, and dendritic cells. The robust recovery of the broad range of the immune system correlated with and supports clinical data showing fewer severe bacterial, fungal, and viral infections in patients treated with omidubicel.
Poster presentation of "Hospitalization and Healthcare Resource Use of Omidubicel vs. Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial" on Monday, December 13, 2021, 6:00-8:00 p.m. ET. Resource utilization data during the first 100 days after transplant were analyzed for 108 patients in the phase III trial and shows that omidubicel-treated patients has significantly shorter durations of hospitalization, intensive care unit time, consultant visits, procedures, and transfusions than the control arm. These data provide further evidence of the clinical benefit associated with the more rapid hematopoietic recovery in patients treated with omidubicel and the corresponding reduction in healthcare resource utilization.
Poster presentation, "Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center" on Saturday, December 11, 2021, 5:30-7:30 p.m. ET. Analysis of outcomes of 22 patients with hematologic malignancies treated with omidubicel at Duke University over a 10-year period shows long-term sustained bone marrow function and immune recovery, with a 10-year overall survival of 48%. These data provide further support for the long-term clinical benefit of omidubicel with long-lasting hematopoietic recovery.
GDA-201: NAM-Enabled NK Cell Therapy

IND for Phase 1/2 Study: Gamida Cell is working to address the clinical hold on the IND for a Phase 1/2 study of GDA-201. As a result of the clinical hold, the initiation of our planned Phase 1/2 study of GDA-201 will be delayed beyond the end of 2021, as the company previously projected.
New data presented at SITC (Free SITC Whitepaper): Gamida Cell recently presented promising new preclinical data in two posters characterizing the NAM-enabled mechanisms of action that contribute to the metabolic modulation properties and enhanced tumor cytotoxicity activity of GDA-201 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 36th Annual Meeting (SITC 2021) held from November 10-14, 2021.
New data to be presented at ASH (Free ASH Whitepaper): A poster titled "GDA-201, A Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-year survival and correlation with cytokine IL7" will be presented at the upcoming ASH (Free ASH Whitepaper) Annual Meeting and Exposition on Monday, December 13, 2021, 6:00-8:00 p.m. ET. This analysis provides longer follow-up in the investigator-led study of GDA-201 in patients with non-Hodgkin lymphoma and demonstrated an overall survival rate of 78% at two years, median duration of response of 16 months, and a safety profile that was similar to what had been previously reported.
NAM-Enabled NK Cell Pipeline Expansion

Advanced NAM-enabled genetically modified NK pipeline: During Gamida Cell’s NK-focused virtual R&D Day, the company presented new data and additional details on its genetically modified NK cell immunotherapy programs, which utilize CAR, membrane bound- and CRISPR-mediated strategies to increase targeting, potency and persistence against hematologic malignancies and solid tumors:
GDA-301: Knockout of CISH (cytokine inducible SH2 containing protein) in NK cells using CRISPR/Cas9 in combination with a membrane-bound IL-15/IL-15Ra;
GDA-501: anti HER2 CAR-engineered NK cells to target solid tumors expressing HER2, based on a single-chain variable fragment of the widely used humanized monoclonal antibody trastuzumab; and
GDA-601: CRISPR Knockout of CD38 on NK cells combined with anti CD38 CAR. CD38 is an established immunotherapeutic target in multiple myeloma, but its expression on NK cells and its further induction during ex vivo NK cell expansion represents a barrier to the development of an anti CD38 CAR-NK cell therapy. Gamida Cell recently announced a research collaboration with the Dana-Farber Cancer Institute to study the in vitro cytotoxicity of GDA-601 in fresh samples from multiple myeloma patients.
New data presented at PEGS Europe: Data from early-stage studies of GDA-501 demonstrated enhanced potency and cytotoxicity against a HER2-expressing tumor cell line. Data presented on GDA-301 showed cytotoxic activity against a chronic myelogenous leukemia cell line (K562) and a multiple myeloma cell line (RPMI). These data were presented at the 13th Annual Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain November 2-4, 2021.
Third Quarter 2021 Financial Results

Research and development expenses in the third quarter of 2021 were $12.4 million, compared to $10.5 million for the same period in 2020. The increase was mainly due to omidubicel commercial manufacturing readiness activities, and the advancement of the GDA-201 program, including broadening scientific capabilities and talent.
Commercial expenses in the third quarter of 2021 were $6.0 million, compared to $1.9 million for the third quarter of 2020. The increase was mainly attributed to progress with omidubicel commercial readiness activities. Going forward, the company anticipates reducing its near-term commercial readiness expenses in line with the revised omidubicel BLA submission timing.
General and administrative expenses were $4.8 million for the third quarter of 2021, compared to $2.7 million for the same period in 2020. The increase was mainly due to professional services and the hiring of key management positions, to support business growth.
Finance income, net, was $3.5 million for the third quarter of 2021, compared to $0.3 million for the third quarter of 2020. The increase was primarily due to non-cash income, resulting from revaluation of warrants offset by convertible note interest expenses.
Net loss for the third quarter of 2021 was $19.6 million, compared to a net loss of $14.8 million for the same period in 2020.

2021 Financial Guidance

Gamida Cell is re-assessing its planned spending and prior financial guidance as a result of the revised timing of the expected omidubicel BLA submission.

Expected Milestones in 2022

Omidubicel

BLA submission to the FDA in the first half of 2022
GDA-201

Initiation of a company-sponsored Phase 1/2 clinical study in NHL in 2022
NK cell pipeline expansion

Establish preclinical proof of concept studies of the NAM-enabled, genetically modified NK therapeutic targets in 2022
Select pipeline candidate(s) for IND enabling studies by end of 2022
Conference Call Information

Gamida Cell will host a conference call today, November 15, 2021, at 8:00 a.m. ET to discuss these financial results and company updates. A live webcast of the conference call can be accessed in the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 4347485. A recording of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Omidubicel

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with blood cancers. Omidubicel is the first bone marrow transplant graft to receive Breakthrough Therapy Designation from the U.S. FDA and has also received Orphan Drug Designation in the U.S. and EU. For more information about omidubicel, please visit View Source

Omidubicel is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

About GDA-201

Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. For more information about GDA-201, please visit View Source

GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

On November 15, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that members of its senior management team will participate in two virtual investor conferences in November (Press release, Repare Therapeutics, NOV 15, 2021, View Source [SID1234595635]). Details are as follows :

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Northland Synthetic Lethality Investor Conference
Date: Wednesday, November 17, 2021
Time: 9:30 a.m. Eastern Time

Piper Sandler Healthcare Conference
Date: Monday, November 29 – Thursday, December 2, 2021

A live webcast of the Northland Synthetic Lethality Investor Conference panel discussions will be available starting Wednesday, November 17, 2021 at 9:30 a.m. Eastern Time in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days.

The prerecorded Piper Sandler Healthcare Conference fireside chat will be available on Monday, November 22, 2021 at 10 a.m. Eastern Time in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days.